KR102058946B1
(ko)
|
2011-04-08 |
2019-12-24 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 치료를 위한 피리미딘 유도체
|
CN107011346B
(zh)
|
2011-11-09 |
2020-06-16 |
爱尔兰詹森科学公司 |
用于治疗病毒感染的嘌呤衍生物
|
AU2013218072B2
(en)
|
2012-02-08 |
2017-08-31 |
Janssen Sciences Ireland Uc |
Piperidino-pyrimidine derivatives for the treatment of viral infections
|
KR102207888B1
(ko)
|
2012-07-13 |
2021-01-26 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염증의 치료를 위한 거대환식 푸린
|
HUE037064T2
(hu)
|
2012-10-10 |
2018-08-28 |
Janssen Sciences Ireland Uc |
Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
|
JP6297055B2
(ja)
|
2012-11-16 |
2018-03-20 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染症の治療のための複素環置換2−アミノ−キナゾリン誘導体
|
EP2958900B1
(en)
|
2013-02-21 |
2019-04-10 |
Janssen Sciences Ireland Unlimited Company |
2-aminopyrimidine derivatives for the treatment of viral infections
|
EA202090547A3
(ru)
|
2013-03-29 |
2020-12-30 |
Янссен Сайенсиз Айрлэнд Юси |
Макроциклические деаза-оксипурины для лечения вирусных инфекций
|
MY188071A
(en)
|
2013-05-24 |
2021-11-16 |
Janssen Sciences Ireland Uc |
Pyridone derivatives for the treatment of viral infections and further diseases
|
ES2645950T3
(es)
|
2013-06-27 |
2017-12-11 |
Janssen Sciences Ireland Uc |
Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
|
CN105492446B
(zh)
|
2013-07-30 |
2018-08-03 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的噻吩并[3,2-d]嘧啶衍生物
|
PT3097102T
(pt)
|
2015-03-04 |
2018-01-22 |
Gilead Sciences Inc |
Compostos de 4,6-diamino-pirido[3,2-d]pirimidina que modulam recetor do tipo toll
|
CA2995004A1
(en)
|
2015-08-26 |
2017-03-02 |
Gilead Sciences, Inc. |
Deuterated toll-like receptor modulators
|
WO2017048727A1
(en)
*
|
2015-09-15 |
2017-03-23 |
Gilead Sciences, Inc. |
Modulators of toll-like recptors for the treatment of hiv
|
DK3390441T3
(da)
|
2015-12-15 |
2021-10-11 |
Gilead Sciences Inc |
Antistoffer til neutralisering af human immundefekt virus
|
JP6770098B2
(ja)
|
2016-05-27 |
2020-10-14 |
ギリアード サイエンシーズ, インコーポレイテッド |
Ns5a、ns5bまたはns3阻害剤を使用する、b型肝炎ウイルス感染症を処置するための方法
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
CN109476675B
(zh)
*
|
2016-07-01 |
2022-12-09 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的二氢吡喃并嘧啶衍生物
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
AU2017318601B2
(en)
|
2016-09-02 |
2020-09-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
PE20190732A1
(es)
*
|
2016-09-09 |
2019-05-23 |
Novartis Ag |
Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
|
WO2018060317A1
(en)
|
2016-09-29 |
2018-04-05 |
Janssen Sciences Ireland Uc |
Pyrimidine prodrugs for the treatment of viral infections and further diseases
|
IL265921B1
(en)
|
2016-10-14 |
2024-01-01 |
Prec Biosciences Inc |
Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome
|
TWI784370B
(zh)
|
2017-01-31 |
2022-11-21 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
TWI687415B
(zh)
|
2017-08-17 |
2020-03-11 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
AU2018319538B9
(en)
|
2017-08-22 |
2021-05-27 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
WO2019057158A1
(zh)
*
|
2017-09-22 |
2019-03-28 |
江苏恒瑞医药股份有限公司 |
稠合杂芳基衍生物、其制备方法及其在医药上的应用
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
AU2018385693A1
(en)
|
2017-12-15 |
2020-06-18 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
US10966999B2
(en)
|
2017-12-20 |
2021-04-06 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド
|
EP4227302A1
(en)
|
2018-02-13 |
2023-08-16 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
KR102587510B1
(ko)
|
2018-02-15 |
2023-10-11 |
길리애드 사이언시즈, 인코포레이티드 |
피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
|
TWI745652B
(zh)
|
2018-02-16 |
2021-11-11 |
美商基利科學股份有限公司 |
用於製備有療效化合物之方法及中間物
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hbv複製阻害剤としての置換ピロリジン化合物
|
TWI772370B
(zh)
*
|
2018-02-26 |
2022-08-01 |
瑞士商諾華公司 |
作為胞內體類鐸(toll-like)受體抑制劑之化合物及組合物
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
2,4-二胺基喹唑啉衍生物及其醫學用途
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
CN111954675A
(zh)
|
2018-04-06 |
2020-11-17 |
捷克共和国有机化学与生物化学研究所 |
3’3’-环二核苷酸
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
KR102591947B1
(ko)
|
2018-04-19 |
2023-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
PE20210685A1
(es)
|
2018-07-03 |
2021-04-08 |
Gilead Sciences Inc |
Anticuerpos que se dirigen al gp120 de vih y metodos de uso
|
KR102629921B1
(ko)
|
2018-07-06 |
2024-01-31 |
길리애드 사이언시즈, 인코포레이티드 |
치료 헤테로시클릭 화합물
|
WO2020010200A1
(en)
|
2018-07-06 |
2020-01-09 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
PT3820572T
(pt)
|
2018-07-13 |
2023-11-10 |
Gilead Sciences Inc |
Inibidores pd-1/pd-l1
|
KR20210033492A
(ko)
|
2018-07-16 |
2021-03-26 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 치료를 위한 캡시드 억제제
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
CA3111784A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Methods and compositions for the treatment of disease with immune stimulatory conjugates
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
AU2019366355B2
(en)
|
2018-10-24 |
2022-10-13 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
CN113227089A
(zh)
|
2018-10-31 |
2021-08-06 |
吉利德科学公司 |
作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
MX2021009496A
(es)
|
2019-02-08 |
2021-09-08 |
Progeneer Inc |
Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo.
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
CN113543851A
(zh)
|
2019-03-07 |
2021-10-22 |
捷克共和国有机化学与生物化学研究所 |
2’3’-环二核苷酸及其前药
|
KR20210137518A
(ko)
|
2019-03-07 |
2021-11-17 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202231277A
(zh)
|
2019-05-21 |
2022-08-16 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
JP2022536855A
(ja)
|
2019-06-19 |
2022-08-19 |
シルバーバック セラピューティックス インコーポレイテッド |
抗メソテリン抗体およびそのイムノコンジュゲート
|
US20210009718A1
(en)
|
2019-06-25 |
2021-01-14 |
Gilead Sciences, Inc. |
FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
|
TW202115056A
(zh)
|
2019-06-28 |
2021-04-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
AU2020315598A1
(en)
|
2019-07-16 |
2022-03-03 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
US20220257619A1
(en)
|
2019-07-18 |
2022-08-18 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
JP7398556B2
(ja)
|
2019-09-30 |
2023-12-14 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hbvワクチン及びhbvを治療する方法
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
WO2021076908A1
(en)
|
2019-10-18 |
2021-04-22 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
WO2021087064A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
US11807625B2
(en)
|
2019-11-26 |
2023-11-07 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of HIV
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
PE20230376A1
(es)
|
2019-12-24 |
2023-03-06 |
Carna Biosciences Inc |
Compuestos moduladores de la diacilglicerol quinasa
|
BR112022014623A2
(pt)
|
2020-02-14 |
2022-09-13 |
Jounce Therapeutics Inc |
Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
|
JP2023514727A
(ja)
|
2020-02-21 |
2023-04-07 |
シルバーバック セラピューティックス インコーポレイテッド |
ネクチン-4抗体コンジュゲートおよびその使用
|
CA3170551A1
(en)
|
2020-03-02 |
2021-09-10 |
Yong Taik Lim |
Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
|
TW202200161A
(zh)
|
2020-03-20 |
2022-01-01 |
美商基利科學股份有限公司 |
4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
|
CA3181922A1
(en)
|
2020-05-01 |
2021-11-04 |
Gilead Sciences, Inc. |
Cd73 inhibiting 2,4-dioxopyrimidine compounds
|
CA3182541A1
(en)
|
2020-05-04 |
2021-11-11 |
Amgen Inc. |
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
|
TW202208355A
(zh)
|
2020-05-04 |
2022-03-01 |
美商安進公司 |
作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
|
WO2021236944A1
(en)
|
2020-05-21 |
2021-11-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
EP4172157A1
(en)
|
2020-06-25 |
2023-05-03 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of hiv
|
WO2022006327A1
(en)
|
2020-07-01 |
2022-01-06 |
Silverback Therapeutics, Inc. |
Anti-asgr1 antibody conjugates and uses thereof
|
WO2022031011A1
(ko)
|
2020-08-04 |
2022-02-10 |
성균관대학교산학협력단 |
동력학적으로 작용하는 아주번트 앙상블
|
EP4194010A1
(en)
|
2020-08-04 |
2023-06-14 |
Progeneer Inc. |
Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
|
US20230346924A1
(en)
|
2020-08-04 |
2023-11-02 |
Progeneer Inc. |
Mrna vaccine comprising adjuvant capable of kinetic control
|
CA3186054A1
(en)
|
2020-08-07 |
2022-02-10 |
Daniel H. BYUN |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
WO2022103758A1
(en)
|
2020-11-11 |
2022-05-19 |
Gilead Sciences, Inc. |
METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
|
TW202304524A
(zh)
|
2021-04-10 |
2023-02-01 |
美商普方生物製藥美國公司 |
Folr1結合劑、其結合物及使用方法
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
TW202310852A
(zh)
|
2021-05-13 |
2023-03-16 |
美商基利科學股份有限公司 |
TLR8調節化合物及抗HBV siRNA療法之組合
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用FLT3L—Fc融合蛋白之方法
|
AU2022299051A1
(en)
|
2021-06-23 |
2023-12-07 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CA3222439A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CN117396478A
(zh)
|
2021-06-23 |
2024-01-12 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
TW202330504A
(zh)
|
2021-10-28 |
2023-08-01 |
美商基利科學股份有限公司 |
嗒𠯤—3(2h)—酮衍生物
|
US11919869B2
(en)
|
2021-10-29 |
2024-03-05 |
Gilead Sciences, Inc. |
CD73 compounds
|
US20230203071A1
(en)
|
2021-12-03 |
2023-06-29 |
Zhimin Du |
Therapeutic compounds for hiv virus infection
|
TW202342447A
(zh)
|
2021-12-03 |
2023-11-01 |
美商基利科學股份有限公司 |
用於hiv病毒感染之治療性化合物
|
TW202337439A
(zh)
|
2021-12-03 |
2023-10-01 |
美商基利科學股份有限公司 |
用於hiv病毒感染之治療性化合物
|
WO2023104165A1
(zh)
*
|
2021-12-08 |
2023-06-15 |
上海维申医药有限公司 |
作为TLR7/8激动剂的吡啶[4,3-d]嘧啶类化合物
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023122581A2
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
TW202400165A
(zh)
|
2022-04-06 |
2024-01-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
TW202400138A
(zh)
|
2022-04-21 |
2024-01-01 |
美商基利科學股份有限公司 |
Kras g12d調節化合物
|
TW202402280A
(zh)
|
2022-07-01 |
2024-01-16 |
美商基利科學股份有限公司 |
可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
US20240083984A1
(en)
|
2022-08-26 |
2024-03-14 |
Gilead Sciences, Inc. |
Dosing and scheduling regimen for broadly neutralizing antibodies
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|